CONTRACT SALES firm Ventiv Health has signed an agreement with Boehringer Ingelheim to expand its existing relationship in support of Boehringer’s primary care sales group.
Financial terms of the deal were not disclosed.
According to Ventiv, the agreement will include “a…
Question: Before Vioxx was recalled, my wife and I both took the pain reliever Mobic. She had to spend two nights in the hospital with symptoms of a heart attack. It was a false alarm, but expensive!
I too had chest discomfort, and my cardiologist did tests. They were negative — and expensive.
I decided Mobic was responsible, and we both stopped it. When the Vioxx story broke, I concluded that these problems were a class effect, but I never saw Mobic mentioned….
WASHINGTON — The first generic forms of meloxicam and venlafaxine have been approved by the Food and Drug Administration.
The former is marketed under the Mobic brand name by Boehringer Ingelheim Ltd. as a treatment for osteoarthritis; the latter, which Wyeth markets under the Effexor trade name, is indicated for the treatment of major depressive disorder.
The clearance of meloxicam was the result of a “clus…
Byline: Adam Cresswell
Most Popular
10 Jobs That Pay $30 An Hour
Public Speaking: 7 Secrets Of Great Public Speakers
Not business as usual: Changing channels in consumer electr…
(meloxicam, Boehringer Ingelheim)
A nonsteroidal anti-inflammatory drug for osteoarthritis.
* Recommended Dosage: Starting at 7.5 mg daily up to 15 mg daily if necessary.
* Special Considerations: GI side-effect rates in Mobic-treated patients in a 12-week study were 17%-20%,…
THE HARTFORD’S TOP 10
DRUGS IN 2005 WORKERS’
COMPENSATION
(RANKED BY TOTAL $ COSTS)
RANK RANK RANK COST INCREASE * COST INCREASE *
DRUG NAME 2005 2004 2003 2005 VS. 2004 2004 VS. 2003
OXYCONTIN 1 1 1 13% 2%
GABAPENTIN 2 N/A N/A 25% -34%
YDROCODONE 3 4 4 -4% -2%
LIDODERM 4 8 11 11% …
Boehringer Ingelheim should stop running a DTC print ad for its COX-2 arthritis inhibitor Mobic (meloxicam) because it contained a misleading comparative claim, the FDA’s Division of Drug Marketing, Advertising and Communications (DDMAC) told the firm in a recent letter.
The ad’s bolded headline,”Att…
